(19)
(11) EP 2 040 753 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
10.04.2019 Bulletin 2019/15

(45) Mention of the grant of the patent:
27.02.2019 Bulletin 2019/09

(21) Application number: 07734620.3

(22) Date of filing: 21.05.2007
(51) International Patent Classification (IPC): 
A61K 45/00(2006.01)
A61K 39/00(2006.01)
(86) International application number:
PCT/IB2007/001312
(87) International publication number:
WO 2007/135542 (29.11.2007 Gazette 2007/48)

(54)

PROGASTRIN INHIBITORS IN THE TREATMENT OF COLON CANCER

PROGASTRIN INHIBITOREN ZUR BEHANDLUNG VON COLONKREBS

TRAITEMENT DE TUMEUR INTESTINALE AVEC DES INHIBITEURES DE PROGASTRINE


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: 22.05.2006 EP 06290823

(43) Date of publication of application:
01.04.2009 Bulletin 2009/14

(73) Proprietors:
  • INSERM (Institut National de la Santé et de la Recherche Médicale)
    75654 Paris Cedex 13 (FR)
  • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS-
    75794 Paris Cedex 16 (FR)
  • Université de Montpellier
    34090 Montpellier (FR)

(72) Inventors:
  • HOLLANDE, Frédéric
    F-34880 Laverune (FR)
  • JOUBERT, Dominique
    F-34400 Saturargues (FR)
  • JAY, Philippe
    F-34980 Combaillaux (FR)
  • PANNEQUIN, Julie
    F-34200 Sète (FR)
  • DELAUNAY, Nathalie
    F-34090 Montpellier (FR)
  • BOURGAUX, Jean-François
    F-30980 Langlade (FR)

(74) Representative: Regimbeau 
20, rue de Chazelles
75847 Paris Cedex 17
75847 Paris Cedex 17 (FR)


(56) References cited: : 
WO-A-2004/089976
WO-A-2006/032980
   
  • LEPORCELET M ET AL: "Small-Molecule Antagonists of the Oncogenic Tcf/Beta-Catenin Protein Complex" CANCER CELL, US, vol. 5, no. 1, January 2004 (2004-01), pages 91-102, XP002984831 ISSN: 1535-6108
  • SIDDHESHWAR R K ET AL: "Plasma levels of progastrin but not amidated gastrin or glycine extended gastrin are elevated in patients with colorectal carcinoma" GUT, vol. 48, no. 1, January 2001 (2001-01), pages 47-52, XP002398546 ISSN: 0017-5749
  • KOYAMA TORU ET AL: "Mutation and expression of the beta-catenin-interacting protein ICAT in human colorectal tumors." JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol. 32, no. 9, September 2002 (2002-09), pages 358-362, XP002398547 ISSN: 0368-2811
  • SINGH P ET AL: "INCOMPLETE PROCESSING OF PROGASTRIN EXPRESSED BY HUMAN COLON CANCER CELLS: ROLE OF NONCARBOXYAMIDATED GASTRINS" AMERICAN JOURNAL OF PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, BETHESDA, MD, US, vol. 266, no. 3,PART 1, 1994, pages G459-G468, XP009057913 ISSN: 0002-9513
  • P. D. OTTEWELL: "COOH-terminal 26-amino acid residues of progastrin are sufficient for stimulation of mitosis in murine colonic epithelium in vivo", AMERICAN JOURNAL OF PHYSIOLOGY: GASTROINTESTINAL AND LIVER PHYSIOLOGY, vol. 288, no. 3, 21 October 2004 (2004-10-21), pages G541-G549, XP055013222, ISSN: 0193-1857, DOI: 10.1152/ajpgi.00268.2004
  • SINGH POMILA ET AL: "Mice overexpressing progastrin are predisposed for developing aberrant colonic crypt foci in response to AOM", 20000301, vol. 278, no. 3 part 1, 1 March 2000 (2000-03-01), pages G390-G399, XP002188103,
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).